The WHO/IUATLD diagnostic algorithm for tuberculosis and empiric fluoroquinolone use: Potential pitfalls

International Journal of Tuberculosis and Lung Disease

Volumn 8, Issue 12, 2004, Pages 1396-1400

  Sterling, Timothy R ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Diagnosis; Fluoroquinolones; Tuberculosis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; GATIFLOXACIN; ISONIAZID; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALGORITHM; ANIMAL MODEL; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; COMMUNITY ACQUIRED PNEUMONIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; LUNG TUBERCULOSIS; MOUSE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SPUTUM SMEAR; TUBERCULOSIS; TUBERCULOSIS CONTROL; WORLD HEALTH ORGANIZATION;

ALGORITHMS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY; WORLD HEALTH ORGANIZATION;

EID: 11244305636     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. World Health Organization, International Union Against Tuberculosis, Royal Netherlands Tuberculosis Association. Revised international definitions in tuberculosis control. Int J Tuberc Lung Dis 2001; 5: 213-215.
2. World Health Organization. Tuberculosis Handbook. WHO/TB/98.253. Geneva, Switzerland: WHO, 1998.
3. American Thoracic Society, Centers for Disease Control and Prevention. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000; 161: 1376-1395.
4. World Health Organization. Global tuberculosis control: WHO Report 2003. WHO/CDS/TB/2003.316. Geneva, Switzerland: WHO, 2003.
5. Siddiqi K, Lambert M L, Walley J. Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence. Lancet Infect Dis 2003; 3: 288-296.
6. Wilkinson D, Newman W, Reid A, Squire S B, Sturm A W, Gilks C F. Trial-of-antibiotic algorithm for the diagnosis of tuberculosis in a district hospital in developing country with high HIV prevalence. Int J Tuberc Lung Dis 2000; 4: 513-518.
7. Wilkinson D, De Cock K M, Sturm A W. Diagnosing tuberculosis in a resource-poor setting: the value of a trial of antibiotics. Trans R Soc Trop Med Hyg 1997; 91: 422-424.
8. Chambers H F, Kocagoz T, Sipit T, Turner J, Hopewell P C. Activity of amoxicillin/clavulanate in patients with tuberculosis. Clin Infect Dis 1998; 26: 874-877.
9. Donald P R, Sirgel F A, Venter A, et al. Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis. Scand J Infect Dis 2001; 33: 466-469.
10. Cynamon M H, Klemens S P, Sharpe C A, Chase S. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1999; 43: 1189-1191.
11. Davies S, Sparham P D, Spencer R C. Comparative in-vitro activity of five fluoroquinolones against mycobacteria. J Antimicrob Chemother 1987; 19: 605-609.
12. Berlin OGW, Young L S, Bruckner D A. In-vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis. J Antimicrob Chemother 1987; 19: 611-615.
13. Yew W W, Piddock L J V, Li M S K, Lyon D, Chan C Y, Cheng AFB. In-vitro activity of quinolones and macrolides against mycobacteria. J Antimicrob Chemother 1994; 34: 343-351.
14. Kennedy N, Fox R, Kisyombe G M, et al. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. Am Rev Respir Dis 1993; 148: 1547-1551.
15. Sirgel F A, Botha F J, Parkin D P, et al. The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 1997; 156: 901-905.
16. Gillespie S H, Billington O. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother 1999; 44: 393-395.
17. Alvirez-Frietes E J, Carter J L, Cynamon M H. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002; 46: 1022-1025.
18. Gosling R D, Uiso L O, Sam N E, et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 168: 1342-1345.
19. Dooley K E, Golub J, Goes F S, Merz W G, Sterling T R. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis 2002; 34: 1607-1612.
20. Pablos-Mendez A, Sterling T R, Frieden T R. The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA 1996; 276: 1223-1228.
21. Sherman L F, Fujiwara P I, Cook S V, Bazerman L B, Frieden T R. Patient and health care system delays in the diagnosis and treatment of tuberculosis. Int J Tuberc Lung Dis 1999; 3: 1088-1095.
22. Sullivan E A, Kreiswirth B N, Palumbo L, et al. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 1995; 345: 1148-1150.
23. Ginsburg A S, Hooper N, Parrish N, et al. Fluoroquinolone resistance in patients with newly-diagnosed tuberculosis. Clin Infect Dis 2003; 37: 1148-1152.
24. Ginsburg A S, Woolwine S C, Hooper N, et al. The rapid development of fluoroquinolone resistance in M. tuberculosis. N Engl J Med 2003; 349: 1977-1978.
25. Bozeman L, Burman W, Gordin F, et al. Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada. Am J Respir Crit Care Med 2002; 165 (Suppl): A18.
26. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. Treatment of Tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
27. O'Brien R J, Nunn P P. The need for new drugs against tuberculosis. Am J Respir Crit Care Med 2001; 162: 1055-1058.
28. Lounis N, Bentoucha A, Truffot-Pernot C, et al. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 2001; 45: 3482-3486.
29. Nuermberger E L, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004; 169: 421-426.
30. Tuberculosis Research Center, Shortening short-course chemotherapy: a randomized clinical trial for treatment of smear-positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Indian J Tuberc 2002; 49: 27-38.
31. File T M. Community-acquired pneumonia. Lancet 2003; 362: 1991-2001.
32. Management of community-acquired pneumonia in adults. S Afr Med J 2002; 92(8 Pt 2): 647-655.
33. Petlman D C, El-Sadr W M, Heifets L B, et al. Susceptibility to levotloxacin of Mycobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. AIDS 1997; 11: 1473-1478.
34. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 1999; 353: 1843-1847.
35. Centers for Disease Control and Prevention. Notice to readers: acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. MMWR 2002; 51: 214-215.
36. Colebunders R, Bastian I. A review of the diagnosis and treatment of smear-negative pulmonary tuberculosis. Int J Tuberc Lung Dis 2000; 4: 97-107.
37. Elliot A M, Namaambo K, Allen B W, et al. Negative sputum smear results in HIV-positive patients with pulmonary tuberculosis in Lusaka, Zambia. Tubercle Lung Dis 1993; 74: 191-194.
38. Alpert P L, Munsiff S S, Gourevitch M N, Greenberg B, Klein R S. A prospective study of tuberculosis and human immunodeficiency virus infection: clinical manifestations and factors associated with survival. Clin Infect Dis 1997; 24: 661-668.
39. Harries A D, Maher D, Nunn P. An approach to the problems of diagnosing and treating adult smear-negative pulmonary tuberculosis in high-HIV-prevalence settings in sub-Saharan Africa. Bull World Health Organ 1998; 76: 651-662.